Alnylam Pharmaceuticals income from continuous operations for the twelve months ending December 31, 2024 was $-0.278B, a 36.82% decline year-over-year.
Alnylam Pharmaceuticals annual income from continuous operations for 2024 was $-0.278B, a 36.82% decline from 2023.
Alnylam Pharmaceuticals annual income from continuous operations for 2023 was $-0.44B, a 61.08% decline from 2022.
Alnylam Pharmaceuticals annual income from continuous operations for 2022 was $-1.131B, a 32.64% increase from 2021.
Alnylam Pharmaceuticals Income from Continuous Operations 2010-2024 | ALNY